GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a ...
Zacks.com on MSN13d
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory DiseasesGSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use ...
https://www.tipranks.com/news/the-fly/cigna-price-target-lowered-to-350-from-400-at-cantor-fitzgerald GSK (GSK) announced that the European Medicines Agency, EMA, has ...
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback